Table 2.
Tumor response.
| Tumor size | All cases | Luminal A-like | Luminal B-like (HER2 negative) | Luminal B-like (HER2 positive) | HER2 overexpression | Triple negative |
|---|---|---|---|---|---|---|
| Pre-NAC echo size (cm), mean ± SD | 5.89 ± 3.27 | 5.83 ± 2.74 | 5.81 ± 3.14 | 5.45 ± 2.50 | 5.90 ± 2.83 | 6.65 ± 4.54 |
| Pathological size (cm), mean ± SD | 2.13 ± 2.08 | 3.31 ± 2.23 |
2.35 ± 2.12 | 1.96 ± 2.23 | 1.64 ± 1.68 | 1.83 ± 1.87 |
| Molecular subtype | Size reduction (%) Median (IQR) | Pairwise comparisonsb |
||||
| Luminal A-like | Luminal B-like (HER2 negative) | Luminal B-like (HER2 positive) | HER2 overexpression | Triple negative |
||
| Luminal A-like | 47.4 (32.8) | – | ||||
| Luminal B-like (HER2 negative) | 57.6 (53.7) | NS | – | |||
| Luminal B-like (HER2 positive) | 69.3 (47.0) | 0.020 | NS | – | ||
| HER2 positive (non-luminal) | 84.4 (46.0) | 0.001 | 0.034 | NS | – | |
| Triple negative (ductal) | 78.8 (56.8) | 0.006 | NS | NS | NS | – |
| p valuea | <0.001 | |||||
| Luminal A-like | Luminal B-like (HER2 negative) | Luminal B-like (HER2 positive) | HER2 overexpression | Triple negative |
||
| Pathological response | ||||||
| pCR | 29 (11.0%) | 0 | 4 (4.2%) | 8 (16.0%) | 7 (15.6%) | 10 (20.4%) |
| Non-pCR | 234 (89.0%) | 23 (100.0%) | 92 (95.8%) | 42 (84.0%) | 38 (84.4%) | 39 (79.6%) |
| p valuec | 0.007 | |||||
Abbreviations: HER-2: human epidermal growth factor receptor 2; pCR: pathological complete response; mean ± SD, mean ± standard deviation.
a
Kruskal-Wallis Test.
b
Dunn's pairwise tests were carried out for the five pairs of groups.
c
Pearson's Chi-square Test.